Da HIV- proteasehæmmere er CYP3A4- substrater forventes det, at posaconazol vil øge plasmaniveauer af disse antiretrovirale midler.
As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents.